Brexu-cel was the first CD19 CAR-T approved for the treatment of r/r mantle cell lymphoma [16], a B cell lymphoma with extremely poor prognosis when chemoimmunotherapy and Bruton’s tyrosine kinase (BTK) inhibitors are ineffective [17]. Here, BTK is linked to B-cell non-Hodgkin lymphoma.